Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Chief Scientific Officer | October 23, 2023 | October 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date October 23, 2023 · Filed October 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2033-10-22 | Direct | 300,000 |
Reported balance
After 2023-10-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-23 · Grant · Acquired 300,000 · Balance 300,000 F1: Twenty-five percent of the shares subject to the stock option vests on the first anniversary of the grant date of October 23, 2023, and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continuous service as the officer of the Issuer as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent of the shares subject to the stock option vests on the first anniversary of the grant date of October 23, 2023, and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continuous service as the officer of the Issuer as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2023 Filed Oct 24, 2023 23:42 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-23-053508 · doc4.xml · derivative · entry 1 Janhofer Guenter · CIK 0001991537 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-10-22 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the stock option vests on the first anniversary of the grant date of October 23, 2023, and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continuous service as the officer of the Issuer as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.